Cadent Capital Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 22.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,776 shares of the company’s stock after acquiring an additional 327 shares during the period. Cadent Capital Advisors LLC’s holdings in Johnson & Johnson were worth $294,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC increased its position in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Norges Bank acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $4,609,399,000. Providence Capital Advisors LLC increased its position in Johnson & Johnson by 141,974.0% during the 1st quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock worth $30,651,000 after purchasing an additional 4,747,612 shares during the period. Morgan Stanley increased its position in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after purchasing an additional 3,849,148 shares during the period. 68.40% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Down 0.7 %
Shares of Johnson & Johnson stock opened at $155.75 on Friday. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The firm has a market cap of $404.79 billion, a PE ratio of 31.53, a P/E/G ratio of 3.17 and a beta of 0.54. The business’s fifty day moving average is $165.97 and its two-hundred day moving average is $162.24. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were given a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 3.06%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 96.36%.
Analyst Ratings Changes
A number of research firms recently weighed in on JNJ. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Morgan Stanley lowered their price target on Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a report on Thursday, August 31st. Atlantic Securities upped their price target on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Finally, Credit Suisse Group upped their price target on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Nine investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $170.65.
Get Our Latest Analysis on JNJ
Insider Buying and Selling
In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- What Are Trending Stocks? Trending Stocks Explained
- Will the Energy Sector Continue to Outshine the Market?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MarketBeat Week in Review – 9/25 – 9/29
- Canadian Penny Stocks: Can They Make You Rich?
- CarMax Slides On Earnings Disappointment, Time To Celebrate?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
